

PIERRE A. GUERTIN, PhD

PROFILE – SHORT BIO



HIGHLIGHTS

Consultant (VCs, pharmaceutical companies, research centers) | Principal Investigator/Project Manager | Professor and Laboratory Director, (neurological, cardiovascular, metabolic, immune, bowel, bladder, erectile, dermatological problems, cancer) | Biomedical Writer (regulatory clinical trial ICH GCP compliant documents, scientific articles, grant applications) | **Senior Pharma Executive** (founder CEO, CSO) | Serial Entrepreneur (5 biotech/spin-off companies in 20 years, 1 advisory group, 1 consulting firm) | Inventor (18 patent applications) | **Communicator** (175+ publications, speaker) | Manager (**preclinical & clinical studies from bench-to-bedside**) | Editorial Board Member | Congress Organizer | Hands-on experience in fund support, research contracts, tax incentives & **private investments in life sciences** | Specialist in tech-transfer & **translational medicine**.

MAIN ACCOMPLISHMENTS

Discovery and development from bench-to-clinical trials (completed phase IIa trials) of the first small-molecule therapeutic for locomotor function recovery and secondary health problems (cardiovascular, immune, metabolic, dermatological) in patients with chronic spinal cord injury. Discovery and development from bench-to-bedside (completed phase II/III study) of organic products for chronic xerosis, pruritus, and locomotor function recovery in people with paralysis, aging, CNS diseases, and metabolic disorders.

SHORT BIO

Prof. Dr. Guertin is a Canadian neuroscientist who has 30+ years of experience as a researcher in neurosciences and 20 years of experience in science leadership. He holds a Ph.D. (1996) in neurophysiology/neurosciences from the University of Manitoba (Canada). He specialized himself between 1996 and 2000 as a postdoctoral fellow in neuropharmacology (Copenhagen University), neurophysiology (University of Oxford), neurogenetics (University Aix-Marseille), and behavioral neurosciences (University of Montréal). Between 2001 and 2025, he was appointed associate and then full professor in psychiatry and neurosciences (Laval University, Canada) as well as chief executive officer of five (5) spin-off biopharmaceutical companies – NeuroSpina Therapeutics, Eurymedon HealthCare, Nordic Life Science Pipeline, Biosynergis Pharma, and Trienix Pharma. He secured several million dollars in financing from Canadian agencies, private foundations, the US Army/US Department of Defense and venture capital firms to conduct basic research, preclinical and clinical development for eight (8) groundbreaking discoveries including his flagship products, Sqin™, Micselon™, and Spinalon™ which received numerous prizes including the *Seal of Excellence* by the European Commission in 2020. As a leading expert in his field, he is author or co-author of more than 175 publications (regulatory documents, articles, reviews, book chapters, patents, etc.), dozens of grant applications, and acts as editorial board member for 32 international journals as well as referee or reviewer for the Canadian Institutes of Health Research, Natural Sciences & Engineering Research Council, Fonds de Recherche du Québec, and the European Commission for Innovation. Since 2021, Dr Guertin provides mainly his services as a consultant (e.g., scouting new ventures, preliminary assessing the risks and potentials of new technologies, developing clinical plans of development, etc.) for VCs, start-ups, and publicly-listed pharmaceutical companies. He also participates in the top management of biomedical companies.

Address: 7 clos des Sorbiers, 6870 Saint-Hubert, Belgique; 2720 Cirier, Montreal, Qc, Canada
Emails: biosynergis@europe.com ; pierre-a.guertin@fmed.ulaval.ca ; paguertin@yahoo.com
Phone: +32.479.17.26.88 (mobile)
Researchgate: https://www.researchgate.net/profile/Pierre_Guertin/contributions
Wikipedia: https://fr.wikipedia.org/wiki/Pierre_A._Guertin
www: <https://paguertin.wixsite/shortbio>

PIERRE A. GUERTIN, PhD

FULL CV

UNIVERSITY DEGREES

- **1993-96 Ph.D.** Physiology/neurophysiology, U. of Manitoba, **Canada**.
Electrophysiological studies on the role of group I and II reflexes in cat walking.
- **1990-92 M.Sc.** Neurokinetic/neurophysiology, U. of Quebec UQAM, **Canada**.
Electrophysiological and pharmacological studies on the role of brain reticulospinal neurons in lamprey swimming.
- **1986-89 B.Sc.** Kinesiology, U. of Montreal, **Canada**.
Cardiovascular and VO₂max studies in elite athletes during cycling.

PROFESSIONAL POSITIONS

- **2021-pres. Lead Consultant.** Biosynergis Healthscience Consult., Gr. Biosynergis, Luxembourg, **Belgium**.
Role: Founder lead consultant responsible of conducting a wide range of writing (clinical trial documents and grant applications), advising, and executive services for pharmaceutical companies and contract research organizations (e.g., Trienix Pharma, McGill-Lebrun spin-off, Mithra Pharmaceuticals, Estetra SRL, Convert Pharma, Aquilon Pharma, Living Med Biotech, NLC Venture, BGV, Forbion, Seroba, etc.).
- **April 2025-pres. CBDO in residence (Consultant).** Trienix Pharma Inc., **Canada**. Role: Identifying co-development deals with industrial partners.
- **2024-April 2025. CEO in residence (Consultant).** Trienix Pharma Inc., **Canada**. Role: Creation of a biopharmaceutical company - putting in place a team, preparing business plan and plan of preclinical/clinical development, closing two rounds of equity financing (pre-seed and seed).
- **2024-Dec 2025. Senior advisor (Consultant), Canada.** New project related with Dr J-J Lebrun's new discovery for triple negative, resistant breast cancer. Role: Preparation of a new spin-off company derived from McGill University, discussing with VCs for early rounds of equity financing.
- **2024-pres. Examiner/Evaluator/Reviewer of new healthcare projects.** European Innovation Council (EIC), **Belgium**. Consultant-contracted work for the assessment of the technical, scientific and commercial value of new emerging healthcare technologies. Role: Evaluating the grant applications submitted to the EIC for non-dilutive or mixed non-dilutive and dilutive (Bank of Europe) funds.
- **2023-pres. Specialty Consultant.** Estetra SPRL/Mithra Pharmaceuticals (EuroNext MITRA), **Belgium**.
Role : Providing advice for advancing new projects (phase I/IIa trials) in neurology and neurosciences.
- **2022-2023. Project Leader (Consultant).** Estetra/Mithra Pharmaceuticals (EuroNext MITRA), Liège, **Belgium**. Role : Developing new projects (clinical trials and non-clinical studies) in neurology and dermatology (design, phase II trial synopsis, discussions with CRO and KOLs).
- **2005-2023. Medical/Scientific Writer.** Neurospina Therapeutics, Nordic LSP, Eurymedon Healthcare, Biosynergis Pharma, Canada, Luxembourg, Belgium. Role: Writing peer-reviewed articles as well as all main regulatory documents (e.g., IBs, CSRs, study protocols, ICFs, etc.) for preclinical (IND), phase I, phase II, and phase II/III studies in neurology, metabolic disorders, CVDs, and dermatology that meet granting agencies, ERBs, and US, Canadian, and European regulatory authority requirements.
- **2019-2020. Founder CEO/CSO.** BioSynergis Pharma SARL, Wiltz, **Luxembourg**. Role: Senior executive in charge of conducting fund raising, medical writing, and managing activities associated with clinical phase IIb studies in neurology, metabolic disorders, and CVDs.
- **2009-2016. Co-founder CEO/CSO.** Nordic Life Science Pipeline Inc., Quebec, **Canada**. Role: Senior executive involved in fund raising, medical writing, and managing activities associated with clinical pilot studies, phase I and II studies, as well as pivotal phase II/III studies in neurology, metabolic disorders, CVDs, and dermatology.
- **2008-2010. Co-founder VP Scientific Affairs/CSO.** Eurymedon Healthcare Inc., Quebec, **Canada**. Role: Executive supervising scientific development and associated with products in neurology.
- **2005-2010. Founder CEO/CSO.** Neurospina Therapeutics Inc., Quebec, **Canada**. Role: Executive responsible for fund raising, scientific and medical writing, and managing activities associated with clinical phase I enabling studies in neurology, metabolic disorders, and CVDs.
- **2001-2021. Full Professor.** Dept Psychiatry & Neurosciences, U. Laval, Quebec, **Canada**.
Role: Full academic professor in physiology (2001-2008) and psychiatry/neurosciences (2009-2021).

- **2001-2020. Laboratory Director/Principal Investigator.** Neuroscience Unit, CHU de Quebec, Canada. Role: PI supervising basic research/clinical studies in neurosciences/neurology, chronic spinal cord injury.

TRAINING EXPERIENCES

- **2000-01. Post-doctoral position, U. Montreal (Canada).** Physiology/Superv.: Drs. /S.Rossignol and R.Robitaille. 1) Calcium fluxes in dorsal root ganglion neurons studied by two-photon laser microscopy in vivo mice. 2) Locomotor function recovery induced by drugs in an adult paraplegic mouse model.
- **1999-00. Post-doctoral position, U. Aix-Marseille (France)/Neurobiology/ Supervisor:** Dr. C.E. Henderson. Identification of novel genes involved in programmed cell death and differentiation.
- **1999. Post-doctoral position, U. Oxford (UK)/ Pharmacology/ Supervisor:** Dr. S. Greenfield. Development of a novel spinal cord slice preparation from guinea-pigs to study acetylcholinesterase.
- **1996-98. Post-doctoral position, U. Copenhagen (Denmark)/ Physiology/ Supervisor:** Dr. J. Hounsgaard. Plateau potentials and intrinsic voltage oscillations of motoneurons in turtles.
- **1993-96. Ph.D. trainee, U. Manitoba (Canada)/Physiology/ Supervisor:** Dr. D.A. McCrea. Identification of neuronal pathways that mediate proprioceptor reflex during walking in cats.
- **1990-92. M.Sc. trainee, U. Quebec in Montreal (Canada)/Kinanthropology/ Supervisor:** Dr. R. Dubuc. Role of the reticular formation in the control of locomotor activity in lampreys.
- **1989. Research assistant, U. Montreal (Canada)/Physical Education/ Supervisor:** Dr. R. Montpetit. 1) Muscle and cardiovascular physiology of athletes training on treadmill and ergonomic cycle; 2) Introduction to neuroscience and motor control with Prof. Phil Gardiner – electrophysiological study.
- **1988. Research assistant, University of Montreal (Canada)/Kinesiology/ Supervisor:** Dr. Gagnon.

ICH GCP COMPLIANT AND OTHER DRUG DEVELOPMENT DOCUMENTS

- > 75 grant applications (neurosciences, endocrinology, bioengineering/medical device, cosmeceuticals)
- 18 patent applications (writer and co-writer);
- 2 patent applications (main reviewer)
- 10 business presentations to VCs;
- 8 original business plans (7 as writer/1 as co-writer);
- 7 investigator brochures (IBs);
- 7 clinical trial protocols (CTPs) as main writer; 3 protocols as co-writer and reviewer;
- 7 informed consent forms (ICFs);
- 5 clinical development plans (4 as writer/1 as co-writer);
- 5 complete drug product information packages;
- 5 clinical trial contracts with research institutions and CROs;
- 4 in-licensing deal agreements;
- 3 ethic review board (ERB)/institutional review board (IRB) applications;
- 3 protocol synopsis
- 2 ERB-approved ads/flyers for recruitment;
- 2 source documents/clinical report forms;
- 2 regulatory IND/CTA applications;
- 2 final clinical trial reports/full clinical study reports (co-writer);
- 1 pre-IND meeting document with FDA.

PROFESSIONAL SKILLS, STRENGTHS & ACCOMPLISHMENTS

- 30+ year experience in **research** on motor control, CNS, spinal physiology, pharmacology, cancer;
- 30+ year experience as **medical writer** and/or **scientific writer**;
- **Medical, scientific and business writing** (>175 publications as article, review, chapter, patent, abstract);
- **Patent application writing** and filing (>15 applications);
- **Grant application writing** (> 5,5M+ Canadian dollars granted);
- Establishing international collaborations in U.S, Turkish, Denmark, Mexico, Canada, France, Belgium;
- 20-year experience as **laboratory director** involved in supervising research teams, teaching to undergraduate and graduate students in biology, physical therapy, neurosciences, etc;
- 22-year experience as project leader (CNS, CVD, dermatology);
- **Scientific vulgarization** and verbal communication and presentation;
- **Serial entrepreneur** as co-founder and executive leader of 4 biopharmaceutical companies in 15 years;
- 15-year experience in **equity financing searching**;

- Significant business contacts in North America among venture capital firms, private and public funding organizations, both specialty and global pharmaceutical companies involved in CNS and metabolic disorders, contract research organizations, etc.;
- **Contractual negotiation** and reviewing legal documents;
- **Organization of international congresses** and conferences;
- 15-year experience as executive officer (**CEO/CSO**) of biopharmaceutical companies;
- **Science translation** as inventor of 4 CNS drugs and 1 biocosmeceutical product;
- **Goal-oriented developer of clinically relevant drugs** from bench-to bedside;
- Developer of **technological platforms** that eases in vivo drug screening and ID of drug candidates;
- **Hands-on experience in drug development plan, clinical trial design, regulatory affairs and regulatory approval processes** in US/Canada and, to some extent, Europe;
- Global understanding of fiscal R&D tax incentives;
- Leading expertise sought as referee, reviewer and editorial board member internationally

AWARDS & DISTINCTIONS (CAD DOLLARS)

• Fond Recherche Santé Québec-FRSQ Senior	Salary support	300.000 (2008-12)
• CQVB Bio-Innovation Contest	Distinction	15.000 (2006)
• FRSQ (Junior 2)	Salary support	205.693 (2005-08)
• FRSQ (Centre Junior 2)	Salary support	48.391 (2005)
• FRSQ (Centre junior 1)	Salary support	132.000 (2001)
• Canadian Institutes of Health Research	Fellowship	38.500 (2000-01)
• Human Frontier Science Program	Fellowship	55.000 (2000)
• Medical Research Council of Canada	Fellowship	35.000 (1998-99)
• The Rick Hansen Foundation	Fellowship	32.000 (1997-98)
• The Rick Hansen Foundation	Fellowship	32.000 (1996-97)
• The Rick Hansen Foundation	Studentship	15.000 (1995-96)
• The Rick Hansen Foundation	Studentship	15.000 (1994-95)

COMMITTEE MEMBER

- **2017-22.** Canadian Institutes of Health Research-CIHR *College of Reviewers* (invitee until 2022)
- **2016-17.** CIHR grant (*project*) reviewing committee (declined)
- **2011-pres.** Fonds Recherche en Santé (FRQ) reviewing committee (*PDF*)(2011, 2012)
- **2010-11.** External Grant Reviewer, Craig H. Neilsen Foundation (U.S.)
- **2010-15.** Membre of the Cercle des Ambassadeurs (Office du Tourisme de Québec)
- **2009-10.** Invited internal Grant Reviewer, U.S. Congressionally Directed Medical Research Programs (CDMRP-Spinal Cord Injury Research Program, Neural Regeneration and Repair)
- **2008-11.** Extended Committee for Coordination of the CHUQ Neuroscience Department (Axis)
- **2008.** CIHR Internal Grant Reviewer (BSA committee member invitee)
- **2006-08.** FRSQ Reviewing Committee M.Sc. degree studentship (Committee FF6-10M)
- **2006-10** NSERC external Grant Reviewer (e.g., grant no. 326926, 261893, 261869, 312015)
- **2005-06.** CIHR external Grant Reviewer (*BSA*)
- **2004.** Member of the negotiation committee for the unionization of research assistants at the CRCHUL
- **2002.** Member of the Animal Care Committee (ethics committee) of Laval University

EDITOR-IN-CHIEF (EIC), EDITORIAL BOARD MEMBER (EBM) & GUEST EDITOR

- **2020-pres.** Journal of Heart, Tridha Scholars publishing (EBM).
- **2019-pres.** Journal of Spinal Diseases, SciTech-Central Pub (Founder EIC).
- **2017-pres.** Peertechz Journal of Gerontology and Geriatric Research (EIC).
- **2017-pres.** International Journal of Pharmaceutical Sciences and Developmental Research (EIC).
- **2017-pres.** Global Journal of Obesity, Diabetes and Metabolic Syndrome (EIC).
- **2016-17.** EC Orthopaedics Journal (EBM)
- **2016-pres.** Current Opinions in Neurological Science (honourable EBM)
- **2016-pres.** OAT loba Drugs and Therapeutics (EBM)
- **2016-pres.** Journal of Neurology and Experimental Neural Science (EBM)
- **2016-pres.** Sports Medicine and Rehabilitation Journal (EBM)
- **2016-17.** Jacobs Journal of Spine (EBM)

- **2016-17.** International Journal of Clinical & Experimental Dermatology (EBM)
- **2016-pres.** Journal of Dermatology and Clinical Research (EBM)
- **2016-17.** Journal of Pharmacology and Pharmacovigilance (EBM)
- **2016-pres.** Asia Pacific Clinical and Translational Nervous System Diseases (EBM)
- **2016-17.** Current Pharmacological Design (guest editor)
- **2016-pres.** Journal of Current Neurobiology (EMB)
- **2015-17.** Insights in Medical Science (EBM)
- **2015-pres.** SM Journal of Neurology and Neuroscience (EBM)
- **2014-pres.** SAVVY Journal of Aging and Gerontology (EBM)
- **2014-17.** Journal of Novel Physiotherapy and Physical Rehabilitation (EBM)
- **2012-13.** Current Pharmacological Design (executive guest editor)
- **2013-pres.** Applied Scientific Reports (EBM)
- **2012-pres.** Journal of Trauma and Treatment (EBM)
- **2009-pres.** Journal of Bioequivalence & Bioavailability (EBM)
- **2009-pres.** Journal of Bioanalysis & Biomedicine (EBM)
- **2007-16.** Neural Regeneration Research (EBM)

CONGRESS ORGANIZING COMMITTEE MEMBER

- **2020.** GCCTMH meeting, Tokyo, Japan, May 11-13 2020.
- **2019.** Global Congress on Public Health and Nutrition (GCPHN-2019), Valencia, Spain, 26-28 Sept 2019.
- **2019.** Neurology conference, Dubai, AEU, October 15-17 2019.
- **2019.** Pharmacy and Pharmaceutical Sciences Conference, Rome, Italy, July 22-24, 2019.
- **2019.** International conference on nanomedicine and advanced drug delivery. 13th Ed. London, UK, Aug 2019.
- **2019.** International Conference on Pharmaceutical Sciences and Drug delivery”, Nov 18-19, 2019, Milan, Italy.
- **2017.** Organizing Committee Member, Nanotechnology and Nanomaterials 2017. April 24-26, Dubai, UAE.
- **2017.** Organizing Committee Member, 9th International Conference and Exhibition on Analytical and Bioanalytical Techniques. Analytica 2017. September 27-29, Atlanta, USA.
- **2017.** Organizing Committee Member, Biotherapeutics 2017, World Congress on Biotherapeutics. May 22-23, Mexico City, Mexico.
- **2016.** Organizing Committee Member, 3rd Biomedical Engineering Conference. Nov 7-8, Barcelona, Spain.
- **2016.** Organizing Committee Member, 2nd International conference on Drug Discovery & Design. Nov 7-9. Istanbul, Turkey.
- **2016.** Organizing Committee Member, 7th International conference on Analytical & Bioanalytical Techniques. Sept 28-30, Miami, Florida, USA.
- **2016.** Organizing Committee Member, 2nd International conference on Separation Techniques. September 26-28, Valencia, Spain.
- **2016.** Organizing Committee Member, 2nd International conference on Biopharmaceutics. September 14-16, San Antonio, Texas, USA.
- **2016.** Organizing Committee Member, 7th Annual Global Pharma Summit. August 22-24, New Orleans, Louisiana, USA.
- **2016.** Organizing Committee Member, 6th Asia-Pacific Pharma Congress. July 11-13, Kuala Lumpur, Malaysia.
- **2016.** Organizing Committee Member, World Congress and Expo on Pharmaceutics & Drug Delivery Systems. April 21-23, Dubai, UAE.
- **2016.** Organizing Committee Member, 2nd International conference on Current Trends in Mass Spectrometry. July 21-23, Chicago, USA.
- **2016.** Organizing Committee Member, 8th International conference on Pharmaceutics & Novel Drug Delivery Systems. March 7-9, Madrid, Spain.
- **2014.** Organizing Committee Member, International conference on Pharmaceutics and Novel Drug Delivery Systems, March 24-26, San Antonio, Texas, USA.
- **2013.** Organizing Committee Member, 4th international conference on Analytical & Bioanalysis Techniques. Oct 15-17, Las Vegas, USA.
- **2013.** Organizing Committee Member, 2nd International conference on Addiction Research & Therapy. July 22-24, Las Vegas, USA.
- **2012.** Organizing Committee Member, 1st International Conference on Addiction Research. & Therapy.

August 20-22, Las Vegas, USA.

- **2012.** Organizing Committee Member committee, Neuro-2012, May 14-16, Las Vegas, USA.
- **2011.** Organizing Committee Member. Analytica 2011, Dec 12-13, San Francisco, USA.
- **2011.** Scientific Organizing Committee Member, Intern. Conf. & Exhib. Pharma Regulatory Affairs, PHARMA. September, 6-7, Baltimore, Maryland, USA.
- **2011.** Scientific Organizing Committee Member, International Conference on Pharmaceuticals and Novel Drug Delivery. June 7-8, Las Vegas, USA.
- **2010-11.** Scientific Organizing Committee Member, IDDST congress, Beijing, China
- **2009-11.** Chief Organizer of an international meeting potentially held in Quebec City – the 2nd Christopher Reeve Meeting International Meeting on Spinal Cord Injury (cancelled).

NATIONAL & INTERNATIONAL COLLABORATIONS

- DeLeon R.D. (California State University, U.S.)
- Ivanenko Y.P. (IRCCS Fondazione, Italy)
- Lacquantry F. (University of Rome, Italy)
- Diaz-Rios M. (University of Puerto Rico, Puerto Rico)
- Kahsaka H (University of Tokyo, Japan)
- Minassian K. (Medical University of Vienna, Austria)
- Chillibeck P (University of Saskatchewan, Canada);
- Taccola G (Italy)
- McKerracher L (Bioaxone Biosciences, Cambridge, U.S.)
- Vizzard M.A. (University of Vermont, U.S.)
- Delgado-Lezama R (Cinvestav-IPN, Mexico)
- Kinkead R. (Université Laval, Canada)
- Courtois F (University of Quebec in Montreal, Canada)
- Frenette J. (Laval University, Canada)
- Rouillard C. (Université Laval, Canada)
- Lévesque D. (Université de Montréal, Canada)
- Hedlund PB (Scripps Institute, U.S.)
- Hounsgaard J (University of Copenhagen, Denmark)
- McCrea DA (University of Manitoba, Canada)
- Dubuc R. (Université de Montréal, Canada)
- Rossignol S. (Université de Montréal, Canada)
- Henderson CE (University Aix-Marseille, France/Columbia University, U.S.)
- Greenfield S.A. (Oxford University, U.K.)
- Cheron, G. (Université Libre de Bruxelles, Belgium)

OTHER EXTERNAL CONTRIBUTIONS

- **2011.** Session Chairman. Pharmaceuticals & Novel Drug Delivery Systems. Las Vegas, 3-6 Nov.
- **2010.** Session Chairman. CNS. International Congress on Drug Design and Therapeutics, Dubai, 1-4 Feb.

PATENT APPLICATIONS (18)

1. **2016.** Granted European patent (declined and abandoned by applicants). Composition and Method for Inducing or Restoring Locomotor Functions in an Animal. EP1789052 (April 11, 2016).
2. **2016.** US provisional patent application. Composition and Method against dry to very dry skin problems in a person in need thereof. no 62/350,340 (June 15, 2016).
3. **2015.** PCT patent application. Methods and uses for inducing or facilitating defecation in a patient in need thereof. PCT/CA2015/050143
4. **2015.** PCT patent application. Methods and uses for inducing or facilitating micturition in a patient in need thereof. PCT/CA2015/050146
5. **2014.** US provisional patent application. Methods and uses for inducing or facilitating defecation in a patient in need thereof. US61/946,113 (Feb 28, 2014)
6. **2014.** US provisional patent application. Methods and uses for inducing or facilitating micturition in a patient in need thereof. US61/946,097
7. **2013.** Issued Canadian patent no. CA 2578302. Composition and Method for Inducing or Restoring Locomotor Functions in an Animal.

8. **2013.** Methods and uses for inducing or facilitating micturition in patients in need thereof. US61750922 (provisional Jan 10).
9. **2011.** Issued US patent no. 8.012.481. Composition and Method for Inducing or Restoring Locomotor Functions in an Animal. Sept 6, 2011.
10. **2009.** Provisional patent filed on 14th May, 2009 Composition and method of a treatment for inducing and restoring sexual function in paralyzed subjects. (USPTO no. 61/178.086).
11. **2007.** National entry in U.S. Composition and method of a treatment for inducing body locomotor movements. Patent application no. 11662100)
12. **2007.** National entry in Australia, Composition and method of a treatment for inducing body locomotor movements. Patent application no. 2005282155)
13. **2007.** National entry in Europe. Composition and method of a treatment for inducing body locomotor movements. Patent application no. EP1789052)
14. **2007.** Provisional patent filed on Nov 23rd, 2007 Composition and method of a treatment for inducing and restoring sexual function in paralyzed subjects. (applicants: Guertin, Lapointe, Rouleau) as US60/935/039.
15. **2007.** National entry in Canada, Composition and method of a treatment for inducing body locomotor movements. Patent application no. 2578302.
16. **2006.** Provisional patent filed on Sept 29th, 2006 and titled: Composition & method of a treatment for inducing and restoring sexual function in paralyzed subjects. (Guertin, Lapointe, Rouleau) US60/847,927.
17. **2005.** Full international PCT patent application. Composition and method of a treatment for inducing body locomotor movements. Filed on Sept 1st 2005 (PCT/CA2005/001337).
18. **2004.** Provisional patent filed on Sept 7th, 2004 and titled: Composition and method of a treatment for inducing body locomotor movements. (applicant: P.A. Guertin, US Patent & Trade Office, no.60/607,256).

PEER-REVIEWED ARTICLES (127)

1. **Guertin, P.A. (2026).** Preliminary evidence of safety and efficacy of Spinalon™ and its organic analog on treadmill training performances in patients with paralysis or severe mobility impairment (*in preparation*).
2. **Guertin, P.A., Franco, G. (2026).** Optimal use of ProloDopa 125 for strength-endurance cycling performances in a 60-year-old man with Parkinson's disease (*in preparation*).
3. **Guertin, N., Guertin, P.A. (2026).** Long-term consequences of chemotherapy on cardiac dysfunctions and toxicity in cancer survivors: Latest news and updates on the role of chronic inflammatory mechanisms and the anti-inflammatory therapeutic potential of natural compounds and related analogs. *J Cancer and Tumor Research (in press)*.
4. **Guertin, P.A. (2025)** Cardiovascular diseases, vital organ fibrosis, and chronic inflammation associated with high-intensity and/or high-volume exercise training: Double-edged sword effects of vigorous physical activity in elderly people and/or in middle-age cancer therapy-treated patients? *J. Functional Morphol Kinesiol.* In press.
5. **Moreno-Castillo M, Guertin P.A., Manjarrez E (2024).** Acute effects of L-DOPA/carbidopa/buspirone (Spinalon) on rhythmic electrical activity of the lumbosacral spinal cord in cats. *Biomed Pharmacother* 181. PMID: 39541791
6. **Blanchet, Guertin, Pilon, Gorce, Prince (2021).** From Neural Command to Robotic use : The Role of Symmetry/Asymmetry in Postural and Locomotor Activities. *Symmetry* 13(10): 1-13.
7. **Guertin (2021).** The sugar-cancer connection revisited: aren't obesity, cardiovascular and metabolic disorders, the main problems? *JCER* 12(2): 1-5.
8. **Guertin, P.A. (2020).** The benefits of exercise on mental functions, consciousness, and mindfulness. *Current Trends in Neurology* 13: 1-7.
9. **Guertin, P.A. (2020).** Conscious, unconscious, and involuntary control of locomotion and comparable stereotyped motor behaviors. *Journal of Consciousness Exploration & Research* 11(8): 824-31.
10. **Guertin, PA (2020).** Thresholds and Upper Limits of Training-Induced Cardiovascular, Respiratory, Immune, and Musculoskeletal Adaptations in Able-Bodied People and Neurologically Impaired Patient. *Advancements in Cardiovascular Research* 3(2) :, 262-265.
11. **Guertin, PA (2020).** The good, the bad, and the ugly about VO2 Max as a biomarker of healthy aging and life expectancy. *Journal of Heart* 2(1): 16-19.
12. **Guertin, PA (2020).** Sudden cardiac death and other life-threatening cardiovascular problems associated with excessive endurance training. *Journal of Heart* 2(1): 12-15.
13. **Steuer I., Guertin, P.A. (2019).** Central pattern generators in the brainstem and spinal cord: an overview of basic principles, similarities and differences. *Reviews in Neurosciences*; 30(2): 107-164.
14. **Guertin, P.A. (2019).** 3TC consciousness: A novel definition for research in drug development and healthy ageing. *Current Trends in Neurology* 13: 1-7.
15. **Guertin, P.A. (2019).** Medicines to enhance self-consciousness, mindfulness and healthy ageing? *Gerontology & Geriatrics Studies*; 4(3): 1-3.

16. **Guertin, P.A. (2019).** A novel concept introducing the idea of continuously changing levels of consciousness. *Journal of Consciousness Exploration & Research*. 10(6): 600-606.
17. **Guertin, P.A. (2019).** Toxicity, allergenicity and carcinogenicity: Some hope for innovative cosmeceutical products? *Journal for Clinical and Cosmetic Dermatology*; 3(1): 1-3.
18. **Guertin P.A. (2019).** A Central Pattern Generator in the spinal cord for the central control of micturition: an opportunity for first-in-class drug treatments. *Asia Pacific Journal of Clinical Trials: Nervous System Diseases*; 4(1) : 1-2.
19. **Guertin, P.A. (2019).** Promising combinatorial therapeutic approach for neural repair and recovery of voluntary control of locomotion: neural pluripotent cells and CPG activators? *Journal of Bioanalysis and Biomedicine* 11: 134-135.
20. **Guertin, P.A. (2018).** How safe are glycerin and polyglycerin-10 as key ingredients in personal care products? *Journal of Clinical Pharmacology and Toxicology Research* 2018; 1(2) : 1-2.
21. **Guertin, P.A. (2018).** Comparable CNS mechanisms for locomotor rhythm generation and self-consciousness expression. *Journal of Clinical Pharmacology and Toxicology Research*; 1(2): 3-4.
22. **Guertin, P.A. (2018).** Are self-consciousness and mindfulness altered by aging? *International Journal of Aging Research*; 1 :24.
23. **Guertin, P.A. (2018).** Is Propanediol a safer molecule than some other glycols in personal care and anti-aging biocosmeceutical products? *International Journal of Aging Research*; 1 : 23.
24. **Guertin, P.A. (2017).** Cardiovascular disease and cancer associated with neurological problems: Some hope for innovative combinatorial approaches. *Global drugs and therapeutics*, 2 (4) : 1-2 .
25. **Guertin, P.A. (2017).** Cancer therapy-induced cardiotoxicity: Where are we now. *Cardiology and Cardiovascular Medicine*; 1(2): 102-109.
26. **Guertin, P.A. (2017).** Chemotherapy-induced cardiotoxicity: A major underestimated unmet medical need. *Global drugs and therapeutics*, 2 (3): 1-2.
27. Minassian, K., Hofstoetter U, Dzeladini F, **Guertin, P.A.**, Ijspeert A. (2017). The human central pattern generator for locomotion. *Neuroscientist* 23(6): 649-663.
28. **Guertin, P.A. (2017).** Rationale for assessing safety and efficacy of drug candidates alone and in combination with medical devices: the case study of Spinalon. *Current Pharml Design* 23: 1-11.
29. **Guertin, P.A. (2017).** Spinal locomotor systems. *Current Pharmaceutical Design* 23: 12.
30. McMillan D, De Leon R.D., **Guertin P.A.**, Dy C. (2017). The utility of interappendicular connections in bipedal locomotion. *Current Pharmaceutical Design* 23: 13-23.
31. Hofstoetter U.S., Knikou M., Guertin P.A., Minassian K. (2017). Probing the human spinal locomotor circuits by phasic step-induced feedback and by tonic electrical and pharmacological neuromodulation. *Current Pharmaceutical Design* 23: 24-34.
32. Ivanenko Y.P., Gurfinkel V.S., Selionov V.A., Solopova I.A., Sylos-Labini F, **Guertin P.A.**, Lacquaniti F. (2017). Tonic and rhythmic spinal activity underlying locomotion. *Current Pharmaceutical Design* 23: 35-44.
33. Sylos-Labini F, Zago M, **Guertin, P.A.**, Lacquaniti F, Ivanenko Y.P. (2017). Muscle coordination and locomotion in humans. *Current Pharmaceutical Design* 23: 45-54.
34. Diaz-Rios M., **Guertin, P.A.**, Riviera-Oliver M. (2017). Neuromodulation of spinal locomotor networks in rodents. *Current Pharmaceutical Design* 23: 55-65.
35. Taccola G., **Guertin, P.A. (2017).** Multilevel analysis of locomotion in immature preparations suggests innovative strategies to reactivate stepping after spinal cord injury. *Current Pharmaceutical Design* 23: 66-75.
36. Kohsaka H, **Guertin, P.A.**, Nose A. (2017). Neural circuits underlying fly larval locomotion. *Current Pharmaceutical Design* 23: 76-85.
37. Chilibeck P.D., **Guertin, P.A. (2017).** Locomotor training and factors associated with blood glucose regulation after spinal cord injury. *Current Pharmaceutical Design* 23: 86-95.
38. Radhakrishna M, Steuer I, Prince F, Roberts M, Mongeon D, Kia M, Dyck S, Matte G, Vaillancourt M, **Guertin, P.A. (2017).** Double-blind, placebo-controlled, randomized phase I/IIa study (safety and efficacy) with buspirone/levodopa/carbidopa (Spinalon) in subjects with complete AIS A or motor-complete AIS B spinal cord injury. *Current Pharmaceutical Design* 23: 96-105.
39. **Guertin, P.A. (2016).** The safety of CNS and non-CNS products for skin health: Current status and emerging plans for the future. *Journal of Neurology and Experimental Neural Science*: 4: e119.
40. **Guertin, P.A. (2016).** Recovery of locomotor functions: one footstep at a time. *Sports Medicine and Rehabilitation Journal* 1(2): 1010.
41. **Guertin, P.A. (2016).** Biomedical researchers or medical doctors: Who should care about their 'fundamental' differences? *Journal of Neurology and Experimental Neural Science* 4: 1-3.
42. **Guertin, P.A. (2016).** Innovation in medicine: What does it mean? *Current Opinions in Neurological Science* 1(1): 15-17.

43. **Guertin, P.A. (2016).** Stricter regulations and adaptive clinical trial design for safer and more effective skin care products. *Journal of Dermatology & Clinical Research* 4(5): 1086.
44. **Guertin, P.A. (2016).** Readily implementable measures to improve the safety of dermatological, skin care and anti-ageing products. *Journal of Dermatology & Clinical Research* 4(5): 1088.
45. **Guertin, P.A. (2016).** New avenues for reducing intensive care needs in patients with chronic spinal cord injury. *World Journal of Critical Care Medicine* 5(4): 201-203.
46. **Guertin, P.A. (2016).** Could ageing-related chronic skin problems be attributed to neuronal and non-neuronal dysfunctions? *Peertechz Journal of Gerontology and Geriatric Research* 1: 1-2.
47. **Guertin, P.A. (2016).** Epidemiology of dermatological diseases – aging, metabolic diseases and beyond. *Global Drugs and Therapeutics* 1(1): 1-2.
48. **Guertin, P.A. (2016).** Neural control of skin water content: the eccrine sudoriferous gland. *Journal of Neurology and Experimental Science*; 1: 1-3.
49. **Guertin, P.A. (2016).** Neural control of skin water content: the sebaceous gland, a neglected target. *Current Neurobiology* 7(3): 74-76.
50. **Guertin, P.A. (2016).** Drug safety of skin care products – neuro- and non-neuro-mediated actions. *Global Drugs and Therapeutics*; 1(1): 1-2.
51. **Guertin, P.A. (2016).** Neural control of dermatological functions. *Journal of Neurology and Experimental Neural Science*; 2: 1-3.
52. **Guertin, P.A. (2016).** Thinking out of the box for next-generation drugs in neurology. *Neurology and Experimental Neural Science* 1:1-2.
53. **Guertin, P.A. (2016).** Shall hemangioma be considered an unmet medical need. *J Dermatology Clin Res* 4(2): 1067-68.
54. **Guertin, P.A. (2016).** Randomized double-blind study assessing safety and efficacy of SQIN on xerosis in subjects with mobility impairment and paralysis. *Journal of Dermatology and Clinical Research* 4(3): 1074-79.
55. **Guertin, P.A. (2016).** Seven alternative opportunities to overcome the Valley of Death for drug candidates developed by academic researchers. *Asia Pacific Clinical and Translational Nervous System Diseases*; 1(3): 149-151.
56. **Guertin, P.A. (2016).** Can drug combinations ease approval of new promising CNS products? *J Pharmacol and Pharmacovigilance*; 2(1): 1-2.
57. **Guertin, P.A. (2016).** What's needed for approval of fixed-dose combination products? *J Bioequivalence & Bioavailability*; 8(4): 1-2.
58. **Guertin, P.A. (2016).** Could overmedication associated with spinal injuries be treated with one more CNS drug? *J Neurology Therapeutics* 2(4): 15-16.
59. **Guertin P.A. (2016)** New pharmacological approaches against chronic bowel and bladder problems in paralytics. *World Journal of Critical Care Medicine*; 5 (1): 1-6.
60. **Guertin P.A. (2016).** Convergence of strategies and technologies – Next generation biocosmeceuticals and biopharmaceuticals products. *J Bioanalysis and Biomedicine* 8(3): 1-2.
61. Steuer I, Grob M, **Guertin P.A. (2016).** Proof-of-concept of acute drug-elicited defecatory behaviors in spinal cord-transected animals: a model for identifying centrally-acting prokinetic agents. *Brit J Med and Med Res*; 11(5): 1-7.
62. **Guertin P.A. (2016).** A novel approach for innovative pharmaceutical, nutraceutical and biocosmeceutical products: Different types of combination products and co-activation of natural synergistically acting target receptors (CanSATs). *Brit J Med and Med Res*; 11(9): 1-8.
63. **Guertin, P.A. (2016).** Adapted technological platform for screening and identifying compounds capable of in vivo spinal network-mediated ejaculation in non-anesthetized, chronic paraplegic mice. *British Journal of Medicine and Medical Research*: 12(2): 1-7.
64. **Guertin, P.A., Grob M, Steuer I (2016).** Quantitative behavioral method for assessing pharmacologically-induced episodes of micturition in an animal model of urinary retention and detrusor-sphincter dyssynergia. *British Journal of Medicine and Medical Research*.: 11(6): 1-6.
65. **Guertin, P.A. (2015).** Are new drug combinations a solution to both the patent cliff and lack of new CNS products? *Journal of Current Neurobiology* 7(1): 16-18.
66. **Guertin P.A. (2014)** Preclinical evidence supporting the clinical development of central pattern generator-modulating therapies for chronic spinal cord-injured patients. *Front Hum Neurosci* 8 (272): 1-17.
67. **Guertin P. (2013)** Pharmacology and biochemistry of stereotyped motor behaviors. *Curr Pharm Des* 19(24): 4331. PMID 23360281.
68. Merrill L, Girard B, Arms L, **Guertin P.A., Vizzard M.A. (2013).** Neuropeptide/receptor expression and plasticity in micturition pathways. *Current Pharmacological Design* 19(24): 4411-22. PMID 23360273.
69. McKerracher L, **Guertin P.A. (2013).** Rho as a target to promote repair: translation to clinical studies with Cethrin. *Current Pharmacological Design* 19(24):4400-10. PMID 23360272.

70. Delgado-Lezama R, Loeza-Alcocer E, Andres C., Aguilar J, **Guertin P.A.**, Felix R (2013). Extrasynaptic GABA_A receptors in the brainstem and spinal cord: structure and function. *Current Pharmacological Design* 19(24): 4485-97. PMID 23360278.
71. Kinkead R, **Guertin P.A.**, Gulemetova R (2013). Sex, stress and their influence on respiratory regulation. *Current Pharmacological Design* 19(24):4471-84. PMID 23360277.
72. Courtois F, Carrier S, Charvier K, **Guertin P.A.**, Journal M (2013). The control of male sexual responses. *Current Pharmacological Design* 19(24): 4341-56. PMID 23360268.
73. Rouleau P. & **Guertin P.A.** (2013) A valuable animal model of spinal cord injury to study motor dysfunctions, comorbid conditions, and aging associated diseases. *Current Pharmacological Design* 19(24): 4437-47. PMID 23360275.
74. Steuer I., Rouleau P. & **Guertin P.A.** (2013) Pharmacological approaches to chronic spinal cord injury. *Current Pharmacological Design* 19(24): 4423-36. PMID 23360274.
75. **Guertin P.A.** (2013) Pharmacological approaches to chronic spinal cord injury. *Frontiers Neurology*. 3 (183): 1-15. PMID 23403923.
76. Ung R.V., Rouleau P., **Guertin P.A.** (2012). Functional and physiological effects of treadmill training induced by buspirone, carbidopa, and L-Dopa in clenbuterol-treated paraplegic mice. *Neurorehabil Neural Repair* 26: 385-94. PMID 22157146.
77. **Guertin, P** (2012). Two promising novel classes of drug treatment in clinical development for acute and chronic spinal cord injury. *J Neurol Neurophysiol* 3: e107.
78. **Guertin, Ung, Rouleau & Steuer** (2011) Effects on locomotion, muscle, bone and blood induced by a combination therapy eliciting weight-bearing stepping in non-assisted spinal cord-transected mice. *Neurorehabilitation and Neural Repair* 25: 234-42. PMID 20952632.
79. Rouleau, Ayoub, **Guertin** (2011). Traumatic and non-traumatic spinal cord-injured patients in Quebec, Canada: Part 1 – Epidemiological, clinical & functional characteristics. *Open Epidemiology Journal* 4: 131-7.
80. Rouleau, **Guertin** (2011). Traumatic and non-traumatic spinal cord-injured patients in Quebec, Canada: Part 3 – Pharmacological characteristics. *Spinal Cord* 49: 186-95. PMID 20548322.
81. Rouleau, Ayoub, **Guertin** (2010). Traumatic and non-traumatic spinal cord-injured patients in Quebec, Canada: Part 2 – Biochemical profile. *Spinal Cord* 48(11): 819-24. PMID 20458326.
82. **Guertin** (2010). The development of new drug treatments for functional recovery after neurological damage based upon a novel hypothesis driven-technological platform. *Open Conference Proceedings Journal* 1: 137-140.
83. **Guertin, Ung, & Rouleau** (2010). Oral administration of a novel tri-therapy for central pattern generator activation in paraplegic mice: Proof-of-concept of efficacy. *Biotechnology Journal* 5: 421-6. PMID 20349462
84. Ung, Lapointe, Rouleau, **Guertin** (2010) Non-assisted treadmill training does not improve motor recovery and body composition in spinal cord-transected mice. *Spinal Cord* 48(10): 750-5. PMID 20177410
85. Ung, Rouleau, **Guertin** (2010) Effects of co-administration of clenbuterol and testosterone propionate on skeletal muscle in paraplegic mice. *Journal of Neurotrauma* 27: 1129-42. PMID 20482256
86. **Guertin** (2009). Monoaminergic and catecholaminergic activation of the central pattern generator for locomotion following spinal cord injury. *Neural Regeneration Research* 4(11): 1-5.
87. **Guertin** (2009). The mammalian central pattern generator for locomotion. *Brain Research Reviews* 62: 45-56. PMID 19720083
88. **Guertin** (2009). The biotechnology industry: What's next. *Biotechnology Journal* 4: 124-31. 19685466
89. Steuer & **Guertin** (2009). Spinal cord injury research in mice: 2008 review. *Scientific World Journal* 9: 490-8. PMID 19526188
90. **Guertin** (2009). Recovery of locomotor function with combinatory drug treatments designed to synergistically activate specific neuronal networks. *Curr Med Chem* 16(11): 1366-71. 19355892
91. **Guertin & Steuer** (2009). Key central pattern generators of the spinal cord. *J Neurosci Res* 87: 2399-405. PMID 19326451
92. Lapointe, Rouleau, Ung, **Guertin** (2009). Specific role of dopamine D1 receptors in spinal network activation and rhythmic movement induction in vertebrates. *J Physiol* 587(7): 1499-511. PMID 19204052
93. **Guertin & Brochu** (2009). Preliminary evidence of safety following administration of L-DOPA and buspirone in an incomplete monoplegic patient. *Spinal Cord* 47(1): 91-2. PMID 18542088
94. **Guertin** (2008). Anxiolytics may promote locomotor function recovery in spinal cord injury patients. *Neuropsychiatr Dis Treat* 4(4): 759-63. PMID 19043520

95. Ung, Landry, Rouleau, Lapointe, Rouillard, **Guertin (2008)**. Role of 5-HT₂ receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic transection. *European J Neuroscience*, 28(11): 2231-42. PMID 19019202
96. **Guertin (2008)** A technological platform to optimize combinatorial treatment design and discovery for chronic spinal cord injury. *J. Neurosci Res*, 86(14): 3039-51. PMID 18615646
97. **Guertin (2008)**. Can the spinal cord learn and remember? *The Scientific World Journal*, 8: 757-61. PMID 18677430
98. Lapointe, **Guertin (2008)**. Synergistic effects of D1/5 and 5-HT_{1A/7} agonists on locomotor movement induction in complete spinal cord-transected mice. *Journal of Neurophysiology*. 100: 160-8. PMID 18480366
99. Lapointe, **Guertin (2008)**. Tail pinching-induced hindlimb movements are suppressed by clonidine in spinal cord injured mice. *Behavioral Neuroscience*, 122: 576-88. PMID 18513128
100. Lapointe, Ung, Rouleau, **Guertin (2008)**. Effects of spinal alpha-2 adrenoceptor and I1-imidazoline receptor activation on hindlimb movement induction in spinal cord injured mice. *Journal of Pharmacology and Experimental Therapeutics*, 325:994-1006. PMID 18364473
101. Picard, Lapointe, Brown, **Guertin (2008)**. Histomorphometric and densitometric changes in the femora of spinal cord transected mice. *Anatomical Record*, 291: 303-307. PMID 18231968
102. Ung, Lapointe, **Guertin (2008)**. Early adaptive changes in chronic paraplegic mice: a model to study rapid health degradation after spinal cord injury. *Spinal Cord*, 46: 176-80. PMID 17876343
103. Lapointe, Ung, **Guertin (2007)**. Plasticity in sublesionally located neurons following spinal cord injury. *Journal of Neurophysiology*, 98: 2497-2500.
104. Rouleau, **Guertin (2007)**. Early changes in deep vein diameter and biochemical markers associated with thrombi formation after spinal cord injury in mice. *Journal of Neurotrauma* 24: 1406-14.
105. Grob, **Guertin (2007)**. Role of calcium in the pacemaker-like property of spinal motoneurons. *Médecine/Science* 23:64-6.
106. Rouleau, Ung, Lapointe, **Guertin (2007)**. Hormonal and Immunological changes in mice after spinal cord injury. *Journal of Neurotrauma* 24: 367-78.
107. Ung, Lapointe, Tremblay, Larouche, **Guertin (2007)** Spontaneous recovery of hindlimb movements in complete paraplegic mice: a comparison of assessment methods. *Spinal Cord*. 45:367-79.
108. Landry, Rouillard, Levesque, **Guertin (2006)**. Profile of immediate early gene expression in the spinal cord of low-thoracic paraplegic mice. *Behavioral Neuroscience*, 120(6): 1384-8.
109. Lapointe, Ung, Bergeron, Cote, **Guertin (2006)** Strain-dependent recovery of spontaneous hindlimb movements in spinal cord transected mice. *Behavioral Neuroscience*. 120(4): 826-34.
110. Landry, Lapointe, Rouillard, Levesque, Hedlund, **Guertin (2006)**. Contribution of spinal 5-HT_{1A} and 5-HT₇ receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord transected mice. *European Journal of Neuroscience*, 24:535-546.
111. **Guertin**, Hounsgaard (2006). Conditional Intrinsic Voltage Oscillations in Mature Vertebrate Neurons Undergo Specific Changes in Culture. *Journal of Neurophysiology* 95(3): 2024-7.
112. Lapointe, **Guertin (2006)**. The paraplegic mouse: a model with new perspectives for spinal cord injury research. *Médecine/Science* 22(2): 102-3.
113. **Guertin**, Steuer (2005). Ionotropic 5-HT₃ receptor agonist-induced motor responses in the hindlimbs of paraplegic mice. *Journal of Neurophysiology* 94(5): 3397-405.
114. **Guertin (2005)**. Paraplegic mice are leading to new advances in spinal cord injury research. *Spinal Cord*, 43(8): 459-61.
115. **Guertin (2005)**. Semi-quantitative assessment of hindlimb movement recovery without intervention in adult paraplegic mice. *Spinal Cord* 43(3): 162-6.
116. Landry, **Guertin (2004)** Differential effects of 5-HT₁ and 5-HT₂ receptor agonists on hindlimb movements in paraplegic mice. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 28(6): 1053-60.
117. **Guertin (2004)**. Role of NMDA receptor activation in serotonin agonist-induced air-stepping in paraplegic mice. *Spinal Cord*, Mar 42(3):185-190.
118. **Guertin (2004)**. Synergistic activation of the central pattern generator for locomotion by L-DOPA and quipazine in adult paraplegic mice. *Neuroscience Letters*, Mar 358(2): 71-74
119. Landry, Frenette, **Guertin (2004)**. Body weight, limb size and muscular properties of early paraplegic mice. *Journal of Neurotrauma*. 21 (8): 1008-1016.
120. **Guertin, P.A.** and Hounsgaard, J. (1999). Non-volatile general anaesthetics reduce spinal activity by suppressing plateau potentials. *Neuroscience* January, 88 (2): 353-358.
121. **Guertin, P.A.** and Hounsgaard, J. (1999) L-type calcium channels but not N-methyl-D-aspartate receptor channels mediate rhythmic activity induced by cholinergic agonist in motoneurons from turtle spinal cord slices. *Neuroscience Letters*, February, 261 (1-2): 81-4.

122. **Guertin, P.A.** and Hounsgaard, J. (1998). NMDA-induced intrinsic voltage oscillations depend on L-type calcium channels in spinal motoneurons of adult turtles. *Journal of Neurophysiology* 80 (6): 3380-2.
123. **Guertin, P.A.** and Hounsgaard, J. (1998) Chemical and electrical stimulation induce rhythmic motor activity in an in vitro preparation of the spinal cord from adult turtles. *Neuroscience Letters* 245: 5-8.
124. **Guertin, P.** and Dubuc, R. (1997). Effects of stimulating the reticular formation during fictive locomotion in lampreys. *Brain Research* 753 (2): 328334.
125. Angel, M.J., **Guertin, P.**, Jiménez, I. and McCrea, D.A. (1996). Group I extensor afferents evoke disynaptic EPSPs in cat hindlimb extensor motoneurons during fictive locomotion. *Journal of Physiology* 493, 851-861.
126. **Guertin, P.**, Angel, M.J., Perreault, M.-C. and McCrea, D.A. (1995). Ankle extensor group I afferents excite extensors throughout the hindlimb during fictive locomotion in the cat. *Journal of Physiology* 487: 197-209.
127. Perreault, M.-C., Angel, M.J., **Guertin, P.** and McCrea, D.A. (1995). Effects of stimulation of hindlimb flexor group II afferents during fictive locomotion in the cat. *Journal of Physiology* 487: 211-220.

BOOK CHAPTERS (15)

1. **Guertin, P.A.**, Fülleman P. (2026). *Peaks*. Essay. KDP Publishing.
2. **Guertin, P.A.** (2025). *Croire ou Savoir*. Essay. KDP Publishing.
3. **Guertin, P.A.** (2025). *Meditation Ultime pour Tous*. Essay. KDP Publishing.
4. **Guertin, P.A.** (2024). *Sourceum*. Essay, KDP Publishing.
5. **Guertin, P.A.** (2021). 8th chance of an ordinary guy at living enlightenedly. Autobiographical novel (submitted Oct 20th 2020).
6. **Guertin P.A.** (2021). The Spinal Cord: From the laboratory bench to the patient bedside. (in prep).
7. **Guertin, P.A.** (a.k.a. PAJ Guertain) (2018). X-Folia Part III (Ed. Edilivre, Paris, Fr).
8. **Guertin, P.A.** (a.k.a. PAJ Guertain) (2017). X-Folia Part II (Ed. Edilivre, Paris, Fr).
9. **Guertin, P.A.** (a.k.a. PAJ Guertain) (2015). X-Folia Part I (Ed. Edilivre, Paris, Fr).
10. **Guertin (2013)**. The spinal cord: functional organization, diseases, and dysfunctions. In: *Animal Models of Spinal Cord Repair* (Ed. H. Aldskogius), Humana Press (Book chapter, in press).
11. **Guertin (2013)**. No-laminectomy spinal cord-transected murine model. In: *Animal Models of Spinal Cord Repair* (Ed. H. Aldskogius), Springer Protocols, Humana Press, vol 76, 131-148
12. **Guertin (2011)**. Adaptations of the Motor System in Animal Models of Spinal Cord Injury and DisuseBiomechanics, Book 2, ISBN 978-953-307-969-1.
13. **Guertin (2009)**. A novel neuronal network in the spinal cord that may contribute to restore male reproductive function after spinal cord injury. *Recent Res. Devel. Neurosci.*3.
14. **Guertin (2007)**. Characterization of an animal model of chronic paraplegia for the design of novel combinatorial approaches against spinal cord injury-related secondary complications. Eds. *Research Signpost (Kerala, India), Recent Research Developments in Neuroscience, 2 : 75-91.*
15. Grob, M., **Guertin (2007)**. Evidence of learning and memory in the spinal cord. Eds. *Research Signpost (Kerala, India), Recent Research Developments in Neuroscience, 2: 92-100.*

INVITED PRESENTATIONS (30)

1. **Guertin, P.A. (2019)**. Neural control of involuntary/unconscious walking. ULB (invited by G Cheron), Sept.
2. **Guertin, P.A. (2016)**. Co-activation of multiple targets for synergistic actions and superior efficacy. Neurotalk-2016 May 20-22, Beijing, China. (declined for health reasons)
3. **Guertin, P.A. (2016)**. Development of new drug combinations as a solution to the patent cliff problem currently faced by the pharmaceutical industry. World Congress on Pharmaceutics & Drug Delivery Systems. April 21-23, Dubai, UAE.
4. **Guertin, P.A. (2014)**. Development of a technological platform to accelerate drug discovery for chronic spinal cord injury. Institut de Neurosciences de la Timone, Marseille. July 15, 2014.
5. **Guertin, P.A. (2012)**. *Nordic Life Science Pipeline presents*. BioContact Chateau Laurier, Qc, Oct 3rd, 2012.
6. **Guertin, P.A. (2011)**. *Hypothesis-driven & low-throughput screening in vivo to accelerate the development of drug products in neurology*. IDDST congress. Shenzhen. China, 3-6 November.
7. **Guertin, P.A. (2011)**. *Low-Throughput Drug Screening Approach Designed to Accelerate the Development of New Therapeutics for Spinal Cord Injury*. International Conference on Pharmaceutics and Novel Drug Delivery. Las Vegas, June 7-8.
8. **Guertin, P.A. (2010)**. *Réactivation des Circuits Neuronaux de la Marche: Développement d'une Approche Pharmacologique Novatrice pour les Blessés Médullaires Chroniques*. Université Trois-Rivières, Dec 2010.
9. **Guertin, P.A. (2010)**. *Rationale behind the development of combination products in neurology*. IDDST congress. Beijing. China, 23-26 October

10. **Guertin, P.A. (2010).** *Découverte et développement de nouveaux traitements pharmacologiques en neurologie: Règles, stratégies et défis.* Centre Hospitalier Universitaire de Québec, Quebec City, April 12.
11. **Guertin, P.A. (2010).** *Combination therapies for Spinal Cord Injury.* Department of Neuroscience, Drexel University, Philadelphia, 3rd March, 2010.
12. **Guertin, P.A. (2010).** *An innovative approach to functional recovery after neurological damage based upon an hypothesis driven-technological platform and murine models.* 2nd International Conference on Drug Discovery and Therapy, to be held in Dubai, United Emirates, 1-4 February, 2010
13. **Guertin, P.A. (2009).** *An Innovative Approach to Functional Recovery after Neurological Damage Based upon an Hypothesis Driven-Technological Platform and Murine Models.* 7th Annual Congress of International Drug Discovery Science and Technology (IDDST), Shanghai, China, 22-25 October, 2009
14. **Guertin P.A. (2008).** *Neurospina therapeutics presents Spinalon and CLE-106.* BioContact Annual Meeting. Chateau Frontenac, Quebec City, 3-5 Oct.
15. **Guertin, P.A. (2008).** *Le développement récent du modèle de la souris paraplégique afin d'accélérer la recherche et la découverte de nouveaux traitements pour les paraplégiques et tétraplégiques.* Congrès Annuel de l'Ordre Professionnel des Technologistes Médicaux du Québec, Hilton, Québec, 12-14 Juin.
16. **Guertin, P.A. (2008).** *Combination Therapies: A New Trend in the Design of Innovative Drug Treatments for Spinal Cord Injury and other CNS Indications.* 1st International Conference on Drug Design and Discovery, Dubai, Arab Emirates, 4-8 February 2008.
17. **Guertin, P.A. (2007).** *Neurospina therapeutics presents Spinalon and CLE-106.* BioContact Annual Meeting. Chateau Frontenac, Quebec City, 3-5 Oct.
18. **Guertin, P.A. (2007).** *Development of new therapeutics: The Story of Spinalon.* IRP/CDRF/IRST joint meeting, Zurich 6-8 Sept.
19. **Guertin, P.A. (2007).** *The Spinalon Project.* Ontario Neurotrauma and REPAR meeting. Ottawa, 24-25 May.
20. **Guertin, P.A. (2006).** *Traitement pharmacologique pour les animaux paraplégiques.* BioMedex- CQVB Bio-Innovation Contest, Montreal, Hilton Bonaventure, Mont-Royal Room, May 24th.
21. **Guertin, P.A. (2006).** *Development of a novel class of drug treatment for spinal cord injured patients: CPG activators.* Seminar session IV, Functional recovery and compensation. Banff Resort, Canada, 18-20th April.
22. **Guertin, P.A. (2005).** *Spinalon: A new class of drug treatment.* BioJunior session, BioContact, Chateau Frontenac, Quebec City, Oct 5-7.
23. **Guertin, P.A. (2004).** Existence de neurones locomoteurs au niveau lombaire de la moelle épinière : Études des caractéristiques et possibles implications thérapeutiques. Seminar at the Centre de Recherche de l'Université Laval à Robert-Giffard, 1st October.
24. Landry, E., **Guertin, P.A. (2003)** Differential effects induced by 5-HT₁ and 5-HT₂ agonists on induction of spinal stepping in paraplegic mice. Human Frontier Science Program 3rd Invitational Meeting, 6-9th June, Cambridge, UK.
25. **Guertin, P.A.,** Leblond, H., Provencher, J., Lebel, F., L'Esperance, M., Orsal, D., Rossignol, S. (2002) Effects of serotonergic and alpha-2 noradrenergic drugs on locomotor function recovery in paraplegic mice. Human Frontier Science Program 2nd Invitational Annual Meeting, 9-12th June, Ottawa, Canada.
26. **Guertin, P.A., (2000).** Genetic, cellular and network properties of spinal motoneurons. Internal seminar at the Dept Physiology, Emory University, Atlanta, USA
27. **Guertin, P.A., (2000).** Genetic, cellular and network properties of spinal motoneurons. Internal seminar at the Neuroscience Dept, CHUL Research Centre, Quebec, Canada
28. **Guertin, P.A., (1998).** Intrinsic oscillations and network-generated locomotor rhythms in the spinal cord. Internal seminar at the Institute of Clinic Neurobiology, University of Wurzburg, Wurzburg, Germany.
29. **Guertin, P.A., (1998).** Intrinsic oscillations and network-generated locomotor rhythms in the spinal cord. Internal seminar at the Developmental Neurobiology Inst. (IBDM). INSERM U.382.,Marseille, France.

PUBLIC COMMUNICATIONS (41)

1. Radio de Radio-Canada – program Les Années Lumière with Sophie-Andrée Blondin on the continuation of Dr. Guertin's project called Spinalon for spinal cord injury to be undertaken in Belgium, 17 juin 2018.
2. CBC morning with Susan Campbell, interview about Spinalon. October 2nd 2015.
3. Radio of Radio-Canada. Interviewed by Mme Lachaussée about Spinalon. October 1st, 15h45.
4. Radio-Canada TV. Téléjournal at 18h00. Interview with Mrs Nicole Germain, October 1st, 2015.
5. News. Le Soleil/La Presse.com. Une trithérapie pour paraplégiques : une recherche de 4.5 millions \$ en péril. 24 November 2014.
6. Radio of Radio-Canada. Les Années Lumières. Interview with Yanick Villedieu on Spinalon. 25 Oct 2015.
7. News. Radio de Radio-Canada, interview for Première Heure with Claude Bernatchez. http://www.radio-canada.ca/emissions/lib_radio/v3.2/incpages/pop_indexeur.asp?idMedia=6828204&appCode=medianet&ti

- me=2258&json={"idEmission":"40537111001","Date":"2013/09/16","numeroEmission":"2782","urllabas e":"/emissions/premiere_heure/2013-2014"}.
8. News. *Le Soleil* (Québec), 15th of September, 2013, 'Lauréat de la semaine Le Soleil-Radio-Canada. by Pierre Pelchat. P28.
 9. News. Radio-Canada TV. 15th of September, 2013. Lauréat de la semaine Le Soleil Radio Canada. Interview by Guillaume Dumas, 18h27. http://www.radio-canada.ca/regions/quebec/dossiers/detail.asp?Pk_Dossiers_regionaux=448
 10. News. *La Presse* (Montreal), 9th of September. 'Du fauteil roulant au tapis roulant', by Pierre Pelchat. P1-3.
 11. News. *Le Soleil* (Québec), 9th of September, 2013, 'Du fauteil roulant au tapis roulant', by P. Pelchat. P1-3.
 12. News. *La Presse* (Montreal), 9th of September. 'Du fauteil roulant au tapis roulant', by Pierre Pelchat. P1-3.
 13. Report. *CBC Radio* (from cost to cost), 11th of September 2013. Interview by Peter Black, 15 minutes.
 14. News. *LCN Le Matin* (across the Province), 10th of September 2013; by Jean-François Guérin.
 15. News. *106.9 Radio* (Trois-Rivières), 10th of September 2013. 3 minutes.
 16. Press release, *Le Soleil*. 14th October 2004. Les paraplégiques pourraient remarquer trois fois par semaine. Interviewed by Maryline Garneau, p.26.
 17. Radio interview *FM93.3*. 12th October 2004. Live interview by Robert Gillet: Nouveau traitement en voie de brevet pour les paraplégiques. 8h00.
 18. Press release, *The Economic Times* (India). Help's on the way for spinal injury victims. <http://economictimes.indiatimes.com/articleshow/879052.cms>. 15 October 2004
 19. Television interview, *Radio-Canada*. 10th October 2004. Interviewed by Nicole Germain: Une percée médicale porteuse d'espoir. News at 18h00. <http://www.radio-canada.ca/regions/Quebec/nouvelles/200410/10/001-drogue-souris.shtml>
 20. Press release, *Newkerala* (India) A Canadian scientist develops a cure for spinal cord injury. <http://news.newkerala.com/world-news/index.php?action=fullnews&id=35410>. 8 octobre 2004
 21. Press release, *Le Journal de Québec*. Les paraplégiques pourraient marcher trois fois par semaine. Par Maryline Gameau. 14 October 2004) p.26.
 22. Radio interview, *CBC radio Montreal*. 22th April 2004. Interview by Nancy Wood, live news at 12h30.
 23. Press release, *La Presse*, 19th April 2004. Newspaper interview by P.A. Normandin. 'La Marche pour Lutter Contre la Paraplégie'. Published in the section 'Actualités', p.A4.
 24. Press release, *Le Soleil*. 19th April 2004. Newspaper interview by P.A. Normandin. 'La Marche pour Lutter Contre la Paraplégie' published in the section 'Actualités', page A4.
 25. Television interview, *CFCF-TV (CTV)*. 15th April 2004. Interview by John Grant for CFCF-TV Montreal broadcasted on the news at 18h00. 'Scientific advance in the field of spinal research'.
 26. Television interview, *TQS television*. 15th April 2004. Interview by Samir Zakem for TQS Montreal broadcasted on the news at 18h00. 'Un traitement pour la paraplégie'.
 27. Press release, *Le Fil de l'Évènement*. (Laval University) 15 April 2004. Article written by Jean Hamann for the Laval University Official Newspaper. 'Dead Mouse Walking: Des Souris qui Retrottent!'. <http://www.scom.ulaval.ca/Au.fil.des.evenements/2004/04.15/souris.html>
 28. Press Release, *Laval University*. 14th April 2004. Un scientifique restaure temporairement la locomotion chez des souris paraplégiques (written by Jean-Francois Huppé, Relations avec les médias, Université Laval).
 29. Press release, *Les Affaires*. 24th April 2004. Newspaper article. 'Les Paraplégiques pourraient-ils un jour retrouver l'usage de leurs membres' Québec in Action, special section, p.7.
 30. Article, *Découvrir*. 1th March 2004. (Association Francophone pour le Savoir). Article written by Julie Calvé titled: 'Lève-toi et marche!' volume 25, no.2, p. 24.
 31. Communication, *4th World Congress of Scientific Journalists*. Oral communication. Potential new drug treatment to partially restore locomotor functions after spinal cord injury. Marriott, Chateau Champlain, Montreal, Oct 4-8, 2004.
 32. Electronic press release, *Yahoo India* (India). Canadian scientist develops cure for spinal cord injury. <http://in.news.yahoo.com/041008/43/2h6em.html>. 8 October 2004.
 33. Electronic press release, *The Spinal Cord Injury Zone* (USA). Canadian scientist develops cure for spinal cord injury. <http://news.thescizone.com/archives/000441.html>. 8 October 2004.
 34. Electronic press release, *Wikiverse*, A World of Knowledge (USA). Canadian scientist develops cure for spinal cord injury. <http://quebec-city-quebec.wikiverse.org/> 8 octobre 2004
 35. Electronic press release, *Michigan Spinal Cord Injury Lawyer* (Michigan, USA). <http://www.lawyer-search.info/lawyer/michigan-spinal-cord-injury-lawyer/>. October 2004.
 36. Electronic press release, Communiqué de *l'Ambassade Belge au Canada* (Ottawa, ON). http://www.nouv-marche.com/CR/dispatch.cgi/tw.lafondatio_documenta/docProfile/100219/d20040329123529 . 29 mars

- 2004.
37. Electronic press release, *Les Débrouillards* (Québec). Un scientifique permet à des souris paralysées de bouger. Par J.-F. Huppé
http://www.lesdebrouillards.qc.ca/applicationWeb/pages/publique/archives/index.php?Type_Items=0&ID=70
 38. Press release, *Journal de Montreal* (Montreal). Les paraplégiques pourraient se dégourdir les jambes. Written by Marilyne Gameau. 1^{er} novembre 2004, p.39.
 39. Press release, *Au fil des Évènements* (Laval University). Ondes de choc; 'Présence remarquée au kiosque de l'Université Laval, au Congrès International des Journalistes Scientifiques. J.-F. Huppé, p.4, 29 october 2004
 40. Radio interview. CJRC. Nouveau traitement pour paraplégiques. Mr. Brulé, News at 12h00. November 2004.
 41. *Journal de Québec*. Les paraplégiques pourraient marcher trois fois par semaine. M. Gameau. 14/10/2004.

SCIENTIFIC ABSTRACTS AND COMMUNICATIONS (50)

1. **Guertin PA** and Steuer I. (2014). An Animal Model of Surgically-induced Accelerated Aging. Gordon Research Conference. Neurobiology of Brain Disorders. July 27-August 1 (2014) Spain.
2. Gorman GS, Noker PA, Coward LU, Ross D, **Guertin PA**, Jia L (2010) In-vitro and in-vivo drug-drug interaction studies with Spinalon, a combination of buspirone and levodopa/carbidopa for spinal cord injury. FIP Pharmaceutical Sciences World Congress, New Orleans 14-18 November.
3. **Guertin, P.A. (2010)**. A novel hypothesis driven-technological platform that eases and accelerates drug therapy design and discovery after CNS damage. FENS. Amsterdam. July 3-7.
4. **Guertin P.A. (2008)**. Pre-clinical and clinical development of a drug treatment for Central Pattern Generator (CPG) activation and 'reflex' stepping induction. Annual Society for Neuroscience Meeting, Washington, D.C., Nov 18.
5. Ung, R.V. and **Guertin, P.A. (2007)**. Testosterone and clenbuterol differentially prevented changes in body weight, muscle mass and adipose tissue in early chronic paraplegic mice. Society for Neuroscience Annual Meeting. San Diego.
6. Lapointe, N.P. and **Guertin, P.A. (2007)**. Powerful induction of locomotor-like movement in complete paraplegic mice following administration of D_{1/5} and 5-HT_{1A/7} receptor agonists. Society for Neuroscience Annual Meeting. San Diego.
7. Rouleau, P., **Guertin, P.A. (2006)**. 'Could ALS progression be affected by reduced mobility-associated peripheral immunological and hormonal deficiencies?' '2nd Annual Symposium André-Delambre on ALS'. CHUL, Québec, 8-9 sept.
8. Lapointe N.P., **Guertin, P.A. (2006)**. Récupération spontanée des fonctions locomotrices est dépendante de la souche murine. Journée de la Recherche, Faculté de Médecine, Université Laval, Pavillon Alphonse Desjardins, 31 mai.
9. Ung, R.V., **Guertin, P.A. (2006)**. Comparaison des méthodes d'évaluation dans la détection de la récupération spontanée chez des souris paraplégiques. Journée de la Recherche, Faculté de Médecine, Université Laval, Pavillon Alphonse Desjardins, 31 mai.
10. Ung V.R, Landry E.S., **Guertin, P.A. (2005)**. Differential role of 5-HT_{2A} and 5-HT_{2C} receptor subtypes in acute induction of hindlimb movements in early chronic paraplegic mice. Christopher Reeve Paralysis Foundation Annual Meeting, 16-18 September, Boston, Mass.
11. Picard S, Brown JP, Frenette J, Jean S, **Guertin PA (2005)** Bone loss in mice after spinal cord injury; an histomorphometrical, biomechanical & densitometrical study. ASBMR meeting, Philadelphia PA, Sept 15-19.
12. Landry, S.E., Rouillard, C., Levesque, D. and **Guertin, P.A. (2005)** Profile of immediate early gene expression in the lumbar spinal cord of paraplegic mice. Society for Neuroscience. 35th Annual Meeting, 12-16th Nov, Washington, DC.
13. Lapointe, N., **Guertin, P.A. (2005)**. Specific dopamine receptor subtypes associated with hindlimb movement generation in early paraplegic mice Society for Neuroscience. 35th Annual Meeting, 12-16th Nov., Washington, DC.
14. Picard, S., Brown, J., Frenette, J., **Guertin, P.A. (2005)**. Rapid bone losses in early chronic paraplegic mice. Society for Neuroscience. 35th Annual Meeting, 12-16th Nov., Washington, DC
15. Ung R-V, Landry, E.S., Lapointe, N., Rouillard, C., Lévesque, D., **Guertin, P.A. (2005)**. Expression, activation, function of 5-HTR_{2A} in the lumbar spinal cord of adult paraplegic mice. Society for Neuroscience. 35th Annual Meeting, 12-16th Nov., Washington, DC.
16. **Guertin, P.A.**, Lapointe, N., Ung, R.V., Frenette, J., Picard, S., Landry, E.S. (2005). Systemic changes and sublesional neuronal plasticity in chronic paraplegic mice. Society for Neuroscience. 35th Annual Meeting, 12-16th Nov., Washington, DC.
17. Picard, S., Brown, J.P., Frenette, J., Jean, S., **Guertin, P.A. (2005)**. Perte rapide d'intégrité osseuse chez la

- souris adulte paraplégique : Étude histomorphométrique densitométrique et biomécanique. Journée de la Recherche, Faculté de Médecine, Université Laval, Pavillon Alphonse Desjardins, 25 mai.
18. Lapointe, N., **Guertin, P.A. (2005)**. Le rôle spécifique de certaines classes de sous-récepteurs dopaminergiques spinaux dans l'activation des neurones locomoteurs chez des souris paraplégiques. Journée de la Recherche, Faculté de Médecine, Université Laval, Pavillon Alphonse Desjardins, 25 mai.
 19. Landry, E.S., Rouillard, C., Lévesque, D., Guertin, P.A. (2005). Modulation de gènes d'expression précoce au niveau lombaire de la moelle épinière chez la souris paraplégique. Journée de la Recherche, Faculté de Médecine, Université Laval, Pavillon Alphonse Desjardins, 25 mai.
 20. Roth-Ung, V., Landry, E.S., Lapointe, N., Guertin, P.A. (2005). Expression, activation et rôle fonctionnel de la sous-classe de récepteur 5-HT_{2A} localisé au niveau lombaire de la moelle épinière chez la souris paraplégique. Journée de la Recherche, Faculté de Médecine, Université Laval, Pavillon Alphonse Desjardins, 25 mai.
 21. Picard, S., Brown, J., Frenette, J., & **Guertin, P.A. (2005)**. Caractérisation de la perte osseuse chez la souris adulte paraplégique : Étude histomorphométrique et biomécanique. 42^{ième} Journée Scientifique Annuelle "Carlton Auger", Association des Pathologistes du Québec, Manoir Montmorency, Québec 29-30 Oct.2004. Published in *Annales de Pathologie*, Avril 2005, vol 25, no 2. p. 178-191.
 22. **Guertin, P.A.**, Rouillard, C., Lévesque, D., Sawchuk, M., Hochman, S., Landry, E. (2004). Evidence of a specific role for 5-HT_{2A} and 5-HT₇ receptors in hindlimb stepping generation in paraplegic mice. Society for Neuroscience. 34th Annual Meeting, Oct. 23-27, San Diego, CA,
 23. Landry, E., **Guertin, P.A. (2004)**. Implication des récepteurs 5-HT_{2A} et 5-HT₇ dans la production de mouvements locomoteurs chez des souris paraplégiques. Journée de la Médecine, Université Laval, 3 juin 2004.
 24. Landry, E., **Guertin, P.A. (2003)**. Effets différentiels d'agoniste 5-HT₁ et 5-HT₂ sur la marche spinal chez des souris paraplégiques. Journée de la Recherche, Faculté de Médecine, Université Laval, 20 juin 2003.
 25. **Guertin, P.A. (2002)**. Activation of the CPG for locomotion by acute intraperitoneal administration of glutamatergic and serotonergic agonists in adult paraplegic mice. Society for Neuroscience Abstract, 32th Annual Meeting, 2-7th Nov, Orlando.
 26. Leblond, H., L'Esperance, M., Orsal, D., **Guertin, P.**, Provencher, J., Lebel, F., Rossignol, S. (2002). Spinal locomotion in paraplegic mice. Society for Neuroscience Abstract, 32th Annual Meeting, 2-7th Nov, Orlando.
 27. **Guertin, P.A.**, Leblond, H., Provencher, J., Lebel F., L'Espérance, M., Orsal, D., Rossignol, S. (2002) Moyens pharmacologiques pour induire la marche dans un modèle de souris paraplégiques. Journée de la Recherche, Faculté de Médecine, Université Laval, 28 mai, Québec, Canada.
 28. Dudley, Kienitz, Kallenbach, Henderson, **Guertin (2001)** L'expression du gene clusterine pendant le developement de la moelle epiniere chez le rat et la souris. Societe des Neurosciences, 5^e Colloque, F-20, Toulouse, France.
 29. Lafreniere-Roula, **Guertin**, Perreault, McCrea, Jordan (2001) Disturbances in ENG rhythmic activity during fictive locomotion in the cat as clues to the modules of the spinal CPG. 1st Segerfalk Symposium. Principles of Spinal Cord Function, Plasticity and Repair. Ystad Saltsjobad, Sweden.
 30. Dudley, **Guertin**, Henderson (2000) Clusterin and megalin expression in the chick, rat and mouse embryonic spinal cord. FENS 2000 Meeting, Brighton, UK.
 31. Dudley, **Guertin**, Grillet, Iovanna, Mallo (1999) Etude par hybridation in situ "Whole Mount" de la co-expression de gènes dans le pancréas et la moelle épinière de rat. 4th French Neuroscience Meeting, B25, Marseille, France.
 32. **Guertin** , Hounsgaard (1998) Intrinsic voltage oscillations in spinal neurons are mediated by NMDA receptor-channels and/or L-type calcium channels. Society for Neuroscience Abstract, 28rd Annual Meeting, Los Angeles.
 33. Perrier, J-F, **Guertin**, Hounsgaard (1998) Organotypic cultures of the spinal cord of the adult turtle. Society for Neuroscience Abstract, 28rd Annual Meeting, Los Angeles.
 34. **Guertin**, Hounsgaard (1997) General anaesthetics reduce neuronal activity in the spinal cord by abolishing plateau potentials. Society for Neuroscience Abstract, 27rd Annual Meeting, New Orleans, 923.13 p.2371.
 35. **Guertin**, Hounsgaard (1997) General anaesthetics reduce neuronal activity in the spinal cord by abolishing plateau potentials. XXXIII IUPS Congress, St-Petersburg, Russia, P084.40.
 36. **Guertin**, Perreault, McCrea (1995) Organization of the CPG revealed by perturbation of the step cycle evoked by group I afferents. Society for Neuroscience Abstract, 25rd Annual Meeting, San Diego, 277.8.
 37. **Guertin**, Perreault, McCrea (1995) Organization of the CPG revealed by perturbation of the step cycle evoked by group I afferents. Proceedings of the International Symposium on Neuron, Networks, and Motor Behavior, pp.66. University of Arizona, Tucson.
 38. Angel, **Guertin**, McCrea (1995) Ia afferents and locomotion: Resetting the record. Society for Neuroscience Abstract, 25rd Annual Meeting, San Diego 561.6 p.1430.

39. Angel, **Guertin**, McCrea (1995) Ia afferents and locomotion: Resetting the record. International Symposium on Neuron, Networks, and Motor Behavior, pp.66. University of Arizona, Tucson.
40. McCrea, **Guertin**, Angel, Perreault (1995) Combined actions of interneurons and motoneurons produce extension enhancement during fictive locomotion. Society for Neuroscience Abstract, 25rd Annual Meeting, San Diego 561.8 p.1430.
41. McCrea, **Guertin**, Angel, Perreault (1995) Combined actions of interneurons and motoneurons produce extension enhancement during fictive locomotion. International Symposium on Neuron, Networks, and Motor Behavior, pp.66. University of Arizona, Tucson.
42. Perreault, **Guertin**, McCrea (1995) Actions from group II muscle afferents during fictive locomotion are not mediated through the short latency flexion reflex pathways. Society for Neuroscience Abstract, 25rd Annual Meeting, San Diego 561.7 p.1430.
43. Perreault, **Guertin**, McCrea (1995) Actions from group II muscle afferents during fictive locomotion are not mediated through the short latency flexion reflex pathways. International Symposium on Neuron, Networks, and Motor Behavior, pp.66. University of Arizona, Tucson.
44. Angel, **Guertin**, Jiménez, McCrea (1994) Disynaptic autogenic and heterogenic excitation from group I afferents in hindlimb extensor motoneurons during fictive locomotion. Society for Neuroscience Abstract, 24rd Annual Meeting, Miami Beach, 648.7 p.1582.
45. Angel, **Guertin**, Jiménez, McCrea (1994) Acciones excitatorias disinápticas autogénicas y polisinápticas producidas por aferentes del grupo I en motoneuronas extensoras durante la locomoción ficticia del gato. Sociedad Mexicana de Ciencias Fisiológicas, XXXVII Congreso Nacional, Mexico, #0161
46. **Guertin**, Angel, Jiménez, McCrea (1994) Both disynaptic and longer latency interneuronal pathways mediate extension enhancement evoked by group I muscle afferents during fictive locomotion. Society for Neuroscience Abstract, 24rd Annual Meeting, Miami Beach 648.8 p.1582.
47. **Guertin**, Angel, Perreault, Carr, McCrea (1993) Ankle extensor group I afferents excite extensors throughout the hindlimb during MLR-evoked fictive locomotion. Society for Neuroscience Abstract, 23rd Annual Meeting, Washington, D.C. 61.15 p.28.
48. **Guertin**, Angel, Perreault, Carr, McCrea (1993) Ankle extensor group I afferents excite extensors throughout the hindlimb during MLR-evoked fictive locomotion. The Physiologist 36(4), American Physiological Society, Physiology and Pharmacology of Motor Control, San Diego, 14.18 p.A-22.
49. Angel, Perreault, **Guertin**, Carr, McCrea (1993) Stimulation of group II muscle afferents in hindlimb flexor nerves resets the step cycle during MLR-evoked fictive locomotion. Society for Neuroscience Abstract, 23rd Annual Meeting, Washington, D.C., 61.16 p.28.
50. Perreault, Angel, **Guertin**, Carr, McCrea (1993) Stimulation of group II muscle afferents in hindlimb flexor nerves resets the step cycle during MLR-evoked fictive locomotion. The Physiologist 36(4), American Physiological Society, Physiology and Pharmacology of Motor Control, San Diego, 14.7 p.A-20.

MONOGRAPHIES

- **Guertin (1992)** Stimulation de la formation réticulée pendant la locomotion fictive chez la lamproie. M.Sc.Thesis, University of Quebec in Montreal, Quebec, Canada.
- **Guertin (1996)** Central mediation of group I muscle afferent-evoked adaptation of the locomotor cycle in decerebrate cats. Ph.D. Thesis, University of Manitoba, Manitoba, Canada.

MAIN ESTABLISHED CONTACTS AMONG VC AND FINANCIAL LIFE SCIENCES INVESTORS

- | | |
|------------------------------------|-----------------------|
| • Power Corporation of Canada | • H.I.G. Bio Ventures |
| • Teva Canada | • Santé Ventures |
| • Servier Canada | • Sofinnova Ventures |
| • Gilead Canada | • Roche Venture fund |
| • Amorchem | • Pappas Ventures |
| • Le Fonds FTQ | • Domain Associates |
| • Cato Ventures | • Knight Therapeutics |
| • La Caisse de Dépôt et Placements | • BDC Healthcare Fund |
| • CTI | • Versant Partner |
| • Teralys | • Warburg Pincus |
| • NLC Venture | - Forbion |

SCIENTIFIC PRODUCTIVITY HIGHLIGHTS

175+ publications including 124 peer-reviewed articles cited 2363 times; H-index 26 and i10-index 50 (Google Scholar); several million dollars in non-dilutive and dilutive funds; 7 main research programs; 5 promising

discoveries/clinically relevant products since 2004; 18 patent applications; personal best most cited article in 1995 (Guertin, Angel, Perreault, McCrea, J. Physiol) cited 267 times; generally recognized as leading expert on CPGs; best known for his 1st discovery, Spinalon™ also recognized by the industry – CQVB prize – as the most promising new medical products in development in Quebec in 2006; Micselon™ for restoration of micturition function was ranked by CIHR as the best technology in development in Canada in 2012 (ranked no.1 among all projects in translational research).